Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.

摘要: Background Ewing sarcoma (ES) is the second most common paediatric malignant bone tumor. Advances in multi-disciplinary care have resulted significant improvement cure rates over last decades. However, generalization of those results countries traditionally excluded from large cooperative trials has yet to be demonstrated. We report modern for patients with ES Poland. Procedures One hundred and thirty-two were treated using multi-modal therapy during period 2000–2009. Overall survival was estimated by Kaplan–Meier methods compared long-rank test Cox models. Factors predictive outcome our setting analyzed identify distinct risk groups that could help areas improvement. Results The median age at time diagnosis 12.3 years. With a follow-up 5.0 years, 5-year event-free (EFS) OS estimates localized disease 54.88% 68.29%, respectively. For metastatic disease, EFS 36% 42%, There no correlation between stage or site. Patients localized, non-pelvic had better than axial tumors (71% vs. 44%, respectively, P = 0.00073). Treatment failure associated stage, pelvic primary, poor histological response, type local control. Conclusions Successful treatment requires optimal systemic therapy. able replicate protocols. Validation current protocols more limited cancer resources required. Pediatr Blood Cancer 2014;61:2170–2174. © 2014 Wiley Periodicals, Inc.